(19)
(11) EP 3 515 938 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
30.04.2025 Bulletin 2025/18

(45) Mention of the grant of the patent:
08.01.2025 Bulletin 2025/02

(21) Application number: 16916449.8

(22) Date of filing: 21.09.2016
(51) International Patent Classification (IPC): 
C07K 16/28(2006.01)
A61P 35/00(2006.01)
C12N 15/63(2006.01)
C12N 5/20(2006.01)
 A61K 39/395(2006.01)
C12N 15/13(2006.01)
C12N 5/10(2006.01)
(52) Cooperative Patent Classification (CPC):
C07K 16/2818; A61K 2039/505; C07K 2317/24; C07K 2317/33; C07K 2317/34; C07K 2317/56; C07K 2317/74; C07K 2317/76; C07K 2317/92; A61P 35/00
(86) International application number:
PCT/CN2016/099576
(87) International publication number:
WO 2018/053709 (29.03.2018 Gazette 2018/13)

(54)

MONOCLONAL ANTIBODIES TO PROGRAMMED DEATH 1 (PD-1)

MONOKLONALE ANTIKÖRPER GEGEN DEN PROGRAMMIERTEN TOD 1 (PD-1)

ANTICORPS MONOCLONAUX DIRIGÉS CONTRE LA MORT PROGRAMMÉE 1 (PD -1)

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(43) Date of publication of application:
31.07.2019 Bulletin 2019/31

(60) Divisional application:
24184760.7 / 4450616

(73) Proprietors:
  • CSTONE PHARMACEUTICALS
    KY1-1205 Grand Cayman (KY)
  • CSTONE PHARMACEUTICALS (SUZHOU) CO., LTD.
    Jiangsu 215123 (CN)
  • CSTONE PHARMACEUTICALS (SHANGHAI) CO., LTD.
    Shanghai 200000 (CN)

(72) Inventors:
  • ZHENG, Yong
    Shanghai 201203 (CN)
  • LI, Jing
    Lexington, Massachusetts 02420 (US)
  • GOLOLOBOV, Gennady
    Gaithersburg, Maryland 20878 (US)
  • ZHANG, Xinhua
    Shanghai 201209 (CN)
  • YANG, Baotian
    Shanghai 200137 (CN)
  • TANG, Zhewei
    Shanghai 200136 (CN)
  • LI, Dong
    Shanghai 200444 (CN)
  • XU, Jianqing
    Shanghai 201200 (CN)
  • WANG, Zhuozhi
    Millbrae, California 94030 (US)

(74) Representative: Engelhard, Markus 
Boehmert & Boehmert Anwaltspartnerschaft mbB Pettenkoferstrasse 22
80336 München
80336 München (DE)


(56) References cited: : 
WO-A1-2013/148250
WO-A1-2015/112900
WO-A2-2016/127179
 WO-A1-2015/112900
WO-A2-2016/077397
CA-A1- 2 955 541
   
  • ANONYMOUS: "Assessment report OPDIVO International non-proprietary name: nivolumab Procedure No. EMEA/H/C/003985/0000", EMA/CHMP/76688/2015, 23 April 2015 (2015-04-23), pages 1 - 130, XP093186112
  • WANG, C. ET AL.: "In Vitro Characterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, and In Vivo Toxicology in Non-Human Primates", CANCER IMMUNOL RES., vol. 2, 28 May 2014 (2014-05-28), XP055206944
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).